RxDoctor Payments Data

Victor Gunn

Physician Assistant · Clovis, CANPI 1164857058

Payments from drug & device makers

$13,230in general payments, 2019–2025

Across 702 payments — averaging $18.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$1K
  • Novo Nordisk$1K
  • Boehringer Ingelheim$881
  • Lilly USA, LLC$609
  • Pfizer$480
  • plus $7K from 50 others

What the payments were for

  • Food & beverage$13,218100%
  • Education$120%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie128$2,395
Amgen54$1,135
Novo Nordisk57$1,079
Boehringer Ingelheim95$881
Lilly USA, LLC40$609
Pfizer31$480
GSK34$473
AstraZeneca6$447
Novartis28$401
Bayer13$353
Abbott16$352
Esperion Therapeutics, Inc.18$345
Boston Scientific7$283
Otsuka America Pharmaceutical, Inc.14$275
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC17$266
Axsome Therapeutics, Inc.8$213
Antares Pharma, Inc.4$211
Dynavax Technologies Corporation8$184
Biohaven Pharmaceutical Holding Company Ltd.9$182
Corcept Therapeutics3$176
SK Life Science, Inc.5$158
Daiichi Sankyo Inc.8$158
Biohaven Pharmaceuticals, Inc.8$147
Neurocrine Biosciences, Inc.1$140
Viiv Healthcare Company6$139
Takeda Pharmaceuticals U.S.A., Inc.5$117
Exact Sciences5$108
Merck5$106
ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)5$105
Gilead1$101
Lundbeck LLC5$90
Xeris Pharmaceuticals, Inc.4$87
Aimmune Therapeutics, Inc.5$86
Radius Health, Inc.3$82
Sumitomo Pharma America, Inc.4$73
Astellas Pharma US Inc4$72
Johnson & Johnson4$71
Phathom Pharmaceuticals, Inc.4$63
Nestle Healthcare Nutrition Inc.3$61
E.r. Squibb & Sons, L.L.C.3$59
Dexcom, Inc.3$54
Verity Pharmaceuticals Inc.2$49
Halozyme Inc2$47
Teva Pharmaceuticals USA, Inc.2$36
Kowa Pharmaceuticals America, Inc.2$35
Sanofi-aventis U.S. LLC2$32
Mylan Specialty L.p.2$29
Almatica Pharma LLC1$25
Abiomed1$25
Otsuka Pharmaceutical Development & Commercialization, Inc.1$23
Amarin Pharma, Inc.1$21
Tolmar, Inc.1$20
Inspire Medical Systems, Inc.1$20
Scilex Pharmaceuticals Inc.1$19
Nevro Corp.1$16
Currax Pharmaceuticals LLC1$15

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$13,230 in reported general payments places this provider in the 95th percentile of 10,423 physician assistant providers in California.

See all physician assistant providers in California

Medicare billing

Part B allowed, 2024
$95,060
Medicare patients
290
Services billed
1,044

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide225$382,762
FarxigaDapagliflozin Propanediol159$167,042
JardianceEmpagliflozin113$147,054
Repatha SureclickEvolocumab79$99,910
RybelsusSemaglutide28$63,572
MounjaroTirzepatide32$50,407
Trelegy ElliptaFluticasone/Umeclidin/Vilanter39$35,850
TrulicityDulaglutide20$33,647
EliquisApixaban35$28,714
VraylarCariprazine Hcl12$17,017
LinzessLinaclotide19$15,939
BelsomraSuvorexant18$15,091
CreonLipase/Protease/Amylase25$14,521
MyrbetriqMirabegron16$13,540
Ezetimibe227$10,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,079$446,334253 claims
AstraZenecaFarxiga, Symbicort$447$171,759172 claims
Boehringer IngelheimJardiance$881$147,054113 claims
Lilly USA, LLCMounjaro, Trulicity$609$84,05452 claims
AbbVieVraylar, Linzess, Creon, Synthroid$2,395$50,33192 claims
GSKTrelegy Ellipta, Breo Ellipta$473$40,44352 claims
PfizerEliquis$480$28,71435 claims
MerckBelsomra$106$15,09118 claims
Astellas Pharma US IncMyrbetriq$72$13,54016 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 10,423 physician assistant providers in California.

Other physician assistant in Clovis

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →